Characterization of Beta Cell Failure

U

University Hospital Tuebingen

Status

Withdrawn

Conditions

Diabetes
Metabolic Syndrome

Treatments

Drug: GLP-1

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00869102
BET-001

Details and patient eligibility

About

The purpose of this study is to characterise beta cell function in subjects who despite taking part in a diabetes prevention program (life style intervention with diet and exercise) exhibit impaired glucose tolerance and beta cell dysfunction.

Full description

We have identified a subgroup of individuals with a good compliance to lifestyle intervention to prevent diabetes who lose body weight and increase insulin sensitivity, however they remain impaired glucose tolerant. These individuals show a deterioration in insulin secretory function. We will identify a highly selected group of subjects with prediabetes that displays a large defect in insulin secretory function.We will study 50 individuals who display these characteristics and 50 subjects who do not display these characteristics. Their insulin secretion capacity in response to different secretagogues (glucose, GLP-1, arginine) will be studied. We expect to detect new pathophysiologic aspects that lead to beta cell failure particularly in this group.

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Impaired glucose tolerance
  • BMI 16-40 kg/m²

Exclusion criteria

  • chronic disease
  • anemia
  • therapy with insulin or cortisone

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

0 participants in 1 patient group

GLP-1
Experimental group
Treatment:
Drug: GLP-1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems